Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRMakoto Maemondo, Toshihiro Nukiwa, Akira Inoue et al.|New England Journal of Medicine|2010Cited by 5.6k
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer ModelingJuliann Chmielecki, William Pao, Marc Ladanyi et al.|Science Translational Medicine|2011Cited by 530
First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for ChemotherapyAkira Inoue, Koichi Hagiwara, Kunihiko Kobayashi et al.|Journal of Clinical Oncology|2009Cited by 516
Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene MutationsAkira Inoue, Toshihiro Nukiwa, Takuji Suzuki et al.|Journal of Clinical Oncology|2006Cited by 504
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 StudyYukio Hosomi, Satoshi Morita, Shunichi Sugawara et al.|Journal of Clinical Oncology|2019Cited by 483